Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Who Is This Treatment For? Chronic spontaneous urticaria, aka CSU, happens when a person develops itchy hives that persist ... to inflammation and weaken your skin barrier. It is not ...

Living with Chronic Spontaneous Urticaria can be challenging, especially when triggers seem ubiquitous. Here's what you need ...

Keep reading to learn more about the symptoms, causes, diagnosis, and treatment ... hives can stem from physical stimulation, such as scratching or rubbing the skin. This is known as physical ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

This approval is specifically for those who continue to experience symptoms in spite of treatment ... skin condition partly driven by type 2 inflammation, leading to recurring itch and severe hives.

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

stipulates use in patients with uncontrolled CSU despite treatment with H1 antihistamines. "People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...